Aidan Hollis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Aidan Hollis has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
- Paul Grootendorst
Leslie Dan Faculty of Pharmacy, University of Toronto , Toronto, ON M5S 3M2
9 shared publications Thomas Pogge
Yale Philosophy Department
6 shared publications- Arthur Sweetman
McMaster University
5 shared publications Javad Moradpour
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada
4 shared publicationsPaul Grootendorst
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada
4 shared publications- Ali Shajarizadeh
Department of Economics, University of Calgary, 2500 University Dr. N.W., Calgary, AB, T2N 1N4, Canada
3 shared publications
Latest Publications
- Open Access
- 16 May 2026
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 4 (6) , qxag119
The launch and diffusion of new patented medicines by therapeutic value
Introduction: Evidence on the launch and diffusion of therapeutically important new medicines is limited. We examined the launch and diffusion of new patented medicines in 14 countries by therapeutic value. Methods: We analyzed IQVIA MIDAS® quarterly sales data for 422 patented molecules first launched between 2013 and 2021 in any of 14 countries (Australia, Belgium, Canada, France, Germany, Italy, Japan, the Netherlands, Norway, Spain, Sweden, Switzerland, the United Kingdom, and the United States) and followed them for at least 2 years. Therapeutic value for each molecule was obtained from rating agencies in Canada, Germany, France, and the United States. Results: Our main time-to-launch analysis showed that, compared with molecules offering major incremental benefit, those with moderate benefit were launched more quickly in several countries, including Canada, France, the Netherlands, Norway, Sweden, and the United Kingdom. Molecules with little to no benefit were launched even more rapidly in the Netherlands. However, once launched, market share by volume did not change significantly over the first 5 years regardless of therapeutic value level in each country. Conclusion: New patented medicines with major incremental therapeutic benefit might not always be launched faster than other medicines. Strategies to balance pricing with adoption and diffusion warrant further investigation.
- 16 May 2026
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 4 (6) , qxag119
Open AccessThe launch and diffusion of new patented medicines by therapeutic value
Introduction: Evidence on the launch and diffusion of therapeutically important new medicines is limited. We examined the launch and diffusion of new patented medicines in 14 countries by therapeutic value. Methods: We analyzed IQVIA MIDAS® quarterly sales data for 422 patented molecules first launched between 2013 and 2021 in any of 14 countries (Australia, Belgium, Canada, France, Germany, Italy, Japan, the Netherlands, Norway, Spain, Sweden, Switzerland, the United Kingdom, and the United States) and followed them for at least 2 years. Therapeutic value for each molecule was obtained from rating agencies in Canada, Germany, France, and the United States. Results: Our main time-to-launch analysis showed that, compared with molecules offering major incremental benefit, those with moderate benefit were launched more quickly in several countries, including Canada, France, the Netherlands, Norway, Sweden, and the United Kingdom. Molecules with little to no benefit were launched even more rapidly in the Netherlands. However, once launched, market share by volume did not change significantly over the first 5 years regardless of therapeutic value level in each country. Conclusion: New patented medicines with major incremental therapeutic benefit might not always be launched faster than other medicines. Strategies to balance pricing with adoption and diffusion warrant further investigation.
- 19 February 2026
- Published by SAGE Publications in Journal of Interpersonal Violence
Divergent Effects of Conflict Exposure on Gendered Attitudes Toward Intimate Partner Violence in Nigeria
This study examines how exposure to conflict events relates to attitudes toward intimate partner violence (IPV) in Nigeria. Using the geo-referenced Armed Conflict Location and Event Data combined with nationally representative Demographic and Health Surveys, we find that women exposed to regional conflict are 0.556 to 0.689 times less likely to justify IPV across different dimensions ( OR = 0.556, 95% CI [0.452, 0.684] to OR = 0.689, [0.554, 0.857]), conditional on a set of individual- and household-level characteristics. However, we observe the opposite result for men, showing that men exposed to conflict are 1.30 to 1.76 times more likely to justify IPV ( OR = 1.300, [1.097, 1.540] to OR = 1.760, [1.464, 2.116]). The gender gap is statistically significant. We further show that conflict exposure correlates with enhanced household decision-making power for women despite reduced economic compensation, while men face increased employment without corresponding income gains, which may link to different changes in attitudes toward IPV for women and men. This study highlights the need for gender-specific interventions that consider the divergent ways conflict exposure affects women’s and men’s attitudes toward IPV in conflict-affected regions.
- 19 February 2026
- Published by SAGE Publications in Journal of Interpersonal Violence
Divergent Effects of Conflict Exposure on Gendered Attitudes Toward Intimate Partner Violence in Nigeria
This study examines how exposure to conflict events relates to attitudes toward intimate partner violence (IPV) in Nigeria. Using the geo-referenced Armed Conflict Location and Event Data combined with nationally representative Demographic and Health Surveys, we find that women exposed to regional conflict are 0.556 to 0.689 times less likely to justify IPV across different dimensions ( OR = 0.556, 95% CI [0.452, 0.684] to OR = 0.689, [0.554, 0.857]), conditional on a set of individual- and household-level characteristics. However, we observe the opposite result for men, showing that men exposed to conflict are 1.30 to 1.76 times more likely to justify IPV ( OR = 1.300, [1.097, 1.540] to OR = 1.760, [1.464, 2.116]). The gender gap is statistically significant. We further show that conflict exposure correlates with enhanced household decision-making power for women despite reduced economic compensation, while men face increased employment without corresponding income gains, which may link to different changes in attitudes toward IPV for women and men. This study highlights the need for gender-specific interventions that consider the divergent ways conflict exposure affects women’s and men’s attitudes toward IPV in conflict-affected regions.
- Open Access
- 21 October 2025
- Published by BMJ in BMJ Global Health
- Vol. 10 (10) , e020322
Armed conflict and child vaccination in Nigeria: the deprioritised preventive care
This study investigates how armed conflict influenced paediatric vaccination uptake in Nigeria. Combining Demographic and Health Survey data with detailed conflict event information, we examine the relationship between the intensity of reported conflicts near children’s residences and their vaccination probabilities. Our findings reveal that a 1 SD increase in conflict intensity reduced vaccination rates by 0.73–1.80 percentage points (between 2.10% and 4.60% of the mean). The results suggest that beyond disrupting healthcare infrastructure, conflict may affect vaccination rates through demand-side effects, where heightened security risks lead parents to deprioritise preventative health investments. These findings contribute to understanding vaccination challenges in conflict zones and inform targeted immunisation strategies.
- 21 October 2025
- Published by BMJ in BMJ Global Health
- Vol. 10 (10) , e020322
Open AccessArmed conflict and child vaccination in Nigeria: the deprioritised preventive care
This study investigates how armed conflict influenced paediatric vaccination uptake in Nigeria. Combining Demographic and Health Survey data with detailed conflict event information, we examine the relationship between the intensity of reported conflicts near children’s residences and their vaccination probabilities. Our findings reveal that a 1 SD increase in conflict intensity reduced vaccination rates by 0.73–1.80 percentage points (between 2.10% and 4.60% of the mean). The results suggest that beyond disrupting healthcare infrastructure, conflict may affect vaccination rates through demand-side effects, where heightened security risks lead parents to deprioritise preventative health investments. These findings contribute to understanding vaccination challenges in conflict zones and inform targeted immunisation strategies.
- Open Access
- 19 March 2025
- Published by SAGE Publications in Journal of Generic Medicines
- Vol. 21 (2) , 52-60
An assessment of Canada’s revised Patented Medicines (Notice of Compliance) Regulations
Canada has high rates of generic usage, but the mechanisms of ensuring timely generic entry are dysfunctional. Unlike most other countries with a linkage regime in which regulatory approval depends on clearing patent hurdles, Canada does not offer temporary generic exclusivity. Instead, it grants the generic kept out of the market by a patent that is ultimately found invalid or not infringed the opportunity to seek its lost profits from the patentee. The system is unbalanced in that patentees find it profitable to litigate even very weak patents since they sustain a monopoly; while the incentives for generic firms to litigate, even if they expect to win, are very weak. This paper analyzes the incentives of the parties, and proposes possible policy fixes to help rebalance the system.
- 19 March 2025
- Published by SAGE Publications in Journal of Generic Medicines
- Vol. 21 (2) , 52-60
Open AccessAn assessment of Canada’s revised Patented Medicines (Notice of Compliance) Regulations
Canada has high rates of generic usage, but the mechanisms of ensuring timely generic entry are dysfunctional. Unlike most other countries with a linkage regime in which regulatory approval depends on clearing patent hurdles, Canada does not offer temporary generic exclusivity. Instead, it grants the generic kept out of the market by a patent that is ultimately found invalid or not infringed the opportunity to seek its lost profits from the patentee. The system is unbalanced in that patentees find it profitable to litigate even very weak patents since they sustain a monopoly; while the incentives for generic firms to litigate, even if they expect to win, are very weak. This paper analyzes the incentives of the parties, and proposes possible policy fixes to help rebalance the system.
- Open Access
- 20 February 2025
- Published by Elsevier in Public Health in Practice
- Vol. 9, 100594
A Canadian multi-province study of COVID-19 vaccine coverage along area-level social determinants in 2021
- 20 February 2025
- Published by Elsevier in Public Health in Practice
- Vol. 9, 100594
Open AccessA Canadian multi-province study of COVID-19 vaccine coverage along area-level social determinants in 2021
- Open Access
- 12 February 2025
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 22 (2) , e1004540
Predicting patent challenges for small-molecule drugs: A cross-sectional study
Background: The high cost of prescription drugs in the United States is maintained by brand-name manufacturers’ competition-free period made possible in part through patent protection, which generic competitors must challenge to enter the market early. Understanding the predictors of these challenges can inform policy development to encourage timely generic competition. Identifying categories of drugs systematically overlooked by challengers, such as those with low market size, highlights gaps where unchecked patent quality and high prices persist, and can help design policy interventions to help promote timely patient access to generic drugs including enhanced patent scrutiny or incentives for challenges. Our objective was to characterize and assess the extent to which market size and other drug characteristics can predict patent challenges for brand-name drugs. Methods and findings: This cross-sectional study included new patented small-molecule drugs approved by the FDA from 2007 to 2018. Market size, patent, and patent challenge data came from IQVIA MIDAS pharmaceutical quarterly sales data, the FDA’s Orange Book database, and the FDA’s Paragraph IV list. Predictive models were constructed using random forest and elastic net classification. The primary outcome was the occurrence of a patent challenge within the first year of eligibility. Of the 210 new small-molecule drugs included in the sample, 55% experienced initiation of patent challenge within the first year of eligibility. Market value was the most important predictor variable, with larger markets being more likely to be associated with patent challenges. Drugs in the anti-infective therapeutic class or those with fast-track approval were less likely to be challenged. The limitations of this work arise from the exclusion of variables that were not readily available publicly, will be the target of future research, or were deemed beyond the scope of this project. Conclusions: Generic competition does not occur with the same timeliness across all drug markets, which can leave granted patents of questionable merit in place and sustain high brand-name drug prices. Predictive models may help direct limited resources for post-grant patent validity review and adjust policy when generic competition is lacking.
- 12 February 2025
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 22 (2) , e1004540
Open AccessPredicting patent challenges for small-molecule drugs: A cross-sectional study
Background: The high cost of prescription drugs in the United States is maintained by brand-name manufacturers’ competition-free period made possible in part through patent protection, which generic competitors must challenge to enter the market early. Understanding the predictors of these challenges can inform policy development to encourage timely generic competition. Identifying categories of drugs systematically overlooked by challengers, such as those with low market size, highlights gaps where unchecked patent quality and high prices persist, and can help design policy interventions to help promote timely patient access to generic drugs including enhanced patent scrutiny or incentives for challenges. Our objective was to characterize and assess the extent to which market size and other drug characteristics can predict patent challenges for brand-name drugs. Methods and findings: This cross-sectional study included new patented small-molecule drugs approved by the FDA from 2007 to 2018. Market size, patent, and patent challenge data came from IQVIA MIDAS pharmaceutical quarterly sales data, the FDA’s Orange Book database, and the FDA’s Paragraph IV list. Predictive models were constructed using random forest and elastic net classification. The primary outcome was the occurrence of a patent challenge within the first year of eligibility. Of the 210 new small-molecule drugs included in the sample, 55% experienced initiation of patent challenge within the first year of eligibility. Market value was the most important predictor variable, with larger markets being more likely to be associated with patent challenges. Drugs in the anti-infective therapeutic class or those with fast-track approval were less likely to be challenged. The limitations of this work arise from the exclusion of variables that were not readily available publicly, will be the target of future research, or were deemed beyond the scope of this project. Conclusions: Generic competition does not occur with the same timeliness across all drug markets, which can leave granted patents of questionable merit in place and sustain high brand-name drug prices. Predictive models may help direct limited resources for post-grant patent validity review and adjust policy when generic competition is lacking.
- Open Access
- 7 April 2024
- Published by Elsevier in Health Policy
- Vol. 144, 105064
The impact of changing the reference countries on the list prices for patented medicines in Canada: A policy analysis
- 7 April 2024
- Published by Elsevier in Health Policy
- Vol. 144, 105064
Open AccessThe impact of changing the reference countries on the list prices for patented medicines in Canada: A policy analysis
- 22 December 2023
- Published by Springer Nature in Applied Health Economics and Health Policy
- Vol. 22 (2) , 155-164
An Optional Delinked Reward System: Making Pharmaceutical Innovation Work for Everyone
Conflicts over pharmaceutical pricing are driven by the patients’ need for affordable medicines and the producer’s reward for the investments in developing innovative medicines. A single price cannot achieve both goals, as it will either obstruct access by patients or provide too low a return to investors. This has led to calls to “delink” the payment for innovation from the price paid for drugs, so that both goals can be met efficiently and without conflict. However, the details of how best to do that are unclear. This paper proposes a specific implementation for delinking the Optional Delinked Reward System (ODRS), which integrates ideas from numerous pharmaceutical reimbursement systems. The ODRS would allow firms to choose either to negotiate a sales price for a drug (as is the current practice in most countries) or to sell their drug at a low “generic” price with a supplementary “delinked” reward based on assessed health benefit. This model builds on recent innovations in drug reimbursement including the UK’s Antibiotic Subscription Pilot and the Pneumococcal Vaccine Advanced Market Commitment. The ODRS would ensure affordable and immediate access for patients and a fair reward for innovators.
- 22 December 2023
- Published by Springer Nature in Applied Health Economics and Health Policy
- Vol. 22 (2) , 155-164
An Optional Delinked Reward System: Making Pharmaceutical Innovation Work for Everyone
Conflicts over pharmaceutical pricing are driven by the patients’ need for affordable medicines and the producer’s reward for the investments in developing innovative medicines. A single price cannot achieve both goals, as it will either obstruct access by patients or provide too low a return to investors. This has led to calls to “delink” the payment for innovation from the price paid for drugs, so that both goals can be met efficiently and without conflict. However, the details of how best to do that are unclear. This paper proposes a specific implementation for delinking the Optional Delinked Reward System (ODRS), which integrates ideas from numerous pharmaceutical reimbursement systems. The ODRS would allow firms to choose either to negotiate a sales price for a drug (as is the current practice in most countries) or to sell their drug at a low “generic” price with a supplementary “delinked” reward based on assessed health benefit. This model builds on recent innovations in drug reimbursement including the UK’s Antibiotic Subscription Pilot and the Pneumococcal Vaccine Advanced Market Commitment. The ODRS would ensure affordable and immediate access for patients and a fair reward for innovators.
- Open Access
- 15 June 2023
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 11, 1170426
The effect of antibiotic usage on resistance in humans and food-producing animals: a longitudinal, One Health analysis using European data
This paper estimates the effect of antibiotic usage in humans and food-producing animals on the prevalence of resistance in zoonotic bacteria in both humans and animals. Using comprehensive longitudinal data from annual surveillance reports on resistance and usage in Europe, we find that antibiotic usage in food-producing animals and antibiotic usage in humans are independently and causally related to the prevalence of resistance in both humans and animals. The study considers simultaneous and total usage of antibiotics in humans and food-producing animals to identify the marginal effects and joint effects of usage on resistance of both groups. By employing lagged-dependent variable and fixed-effects specifications, we provide a lower and an upper bound on the effects on resistance. The paper also contributes to the scant literature on how antibiotic use in humans is related to resistance in other animals.
- 15 June 2023
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 11, 1170426
Open AccessThe effect of antibiotic usage on resistance in humans and food-producing animals: a longitudinal, One Health analysis using European data
This paper estimates the effect of antibiotic usage in humans and food-producing animals on the prevalence of resistance in zoonotic bacteria in both humans and animals. Using comprehensive longitudinal data from annual surveillance reports on resistance and usage in Europe, we find that antibiotic usage in food-producing animals and antibiotic usage in humans are independently and causally related to the prevalence of resistance in both humans and animals. The study considers simultaneous and total usage of antibiotics in humans and food-producing animals to identify the marginal effects and joint effects of usage on resistance of both groups. By employing lagged-dependent variable and fixed-effects specifications, we provide a lower and an upper bound on the effects on resistance. The paper also contributes to the scant literature on how antibiotic use in humans is related to resistance in other animals.